Here at Union Square Spinal Care, I watch over the watch dogs….sometimes scratching my head in wonder. That’s why I have so little hair! Here is a recent story that needs attention. More and more the FDA slips into being a puppet of the drug and food industries.
By Rory Harrington, 14-Dec-2009
Related topics: Regulation
Each day the US Food and Drug Administration (FDA) dithers in delivering its verdict on the safety of bisphenol A (BPA), its authority is diminished and its credibility wanes.
The hold-up is eroding its ability to lead by failing to give industry and consumers what they are crying out for – a timely, impartial and science-based guide to what is safe and what is not.
But why is it so significant that the FDA decision, promised for 30 November, has yet to be published? After all, it’s only two weeks late. Does it matter?
Yes, it does. BPA has become a litmus test of the FDA’s leadership.
When Dr Margaret Hamburg swept into the agency in May she looked and sounded every inch the ferocious new broom determined to turn the organisation around. After declaring the FDA had failed in its handling of the nationwide outbreak of salmonella caused by contaminated peanuts, observers were further heartened when she trained her laser sights on bisphenol A, the chemical used in polycarbonate baby bottles and food can linings that has been linked to cancer, diabetes and heart problems.
As rock group The Who would say ‘Meet the new boss’. And unlike the veteran singers’ next line, ‘Same as the old boss’, Hamburg and the organisation she headed suddenly seemed very different.
The straight-talking Commissioner vowed to sort out the thorny question of BPA in weeks not months – garnering almost universal praise that here at last was somebody who not only understood the importance of the issue but was prepared to bang some heads together to solve the problem. It was a bold declaration designed to challenge the perception of a food safety body too readily influenced by the industries it was charged with regulating.
And in a world where perception can be reality, it could also explain why BPA has so far failed to trigger the same level of anxiety in Europe. The European Food Safety Authority (EFSA) certainly has its critics but few would dispute the organisation is impartial and not afraid to ruffle industry feathers if that is where the evidence leads. While the FDA has wrestled with its lack of credibility, EFSA has been able to calmly assert that it sees no need to review its stance on BPA. It has provided a clear and consistent position that inspires consumer confidence and stability for industry.
The FDA move was also supposed to assuage the genuine fears of US consumers desperate to know they weren’t inadvertently harming themselves or their families. It was to offer much-need clarity to allow industry to formulate longer-term packaging strategies. This enthusiasm was barely dented when the agency announced more than few weeks later its verdict would not be forthcoming until after Thanksgiving.
Union Square Spinal Care 